Nabriva Therapeutics AG

Nabriva Therapeutics — Technical Presentation (May 2018)

36 slides from Nabriva Therapeutics's technical presentation, May 21, 2018

  1. Slide 1: Safe Harbor and Disclaimer

    Safe Harbor and Disclaimer This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements about our future expectations, plans and prospects, inclu

  2. Slide 2: Nabriva: Addressing the Demand for New Antibiotics

    Nabriva: Addressing the Demand for New Antibiotics Lefamulin, the lead molecule of a new class of antibiotics in clinical development for CABP, demonstrated positive topline results in both the LEAP 1 and LEAP 2 Phase 3 trials, with an NDA filing expected in the fourth quarter of 2018 Pre-commercial

  3. Slide 3: Overview of the Lefamulin Clinical Program

    4 Overview of the Lefamulin Clinical Program Extensive PK/PD Characterization and Preclinical Program with 20 Phase I studies Proof-of-Concept Phase 2 ABSSSI LEAP 1: Efficacy and Safety of IV-to-Oral Lefamulin in Adults with CABP LEAP 2: Efficacy and Safety of Oral Lefamulin in Adults with CABP Pedi

  4. Slide 4: Trial Design and Demographics

    LEAP 2 TRIAL DESIGN and DEMOGRAPHICS

  5. Slide 5: Phase 3 Trial Design

    LEAP 2 Phase 3 Trial Design Oral Administration 6 Lefamulin Moxifloxacin Informed Consent & Baseline Assessments Randomization Early Clinical Response (ECR) Assessment (96 +/- 24 hrs After 1st Dose) End of Treatment Within 2 Days After Last Dose Late Follow Up 30 +/-3 Days After 1st Dose 5 days lefa

  6. Slide 6: Phase 3 Trial Design: FDA and EMA Primary Endpoints

    LEAP 2: Phase 3 Trial Design 7 FDA Primary Endpoint: Early Clinical Response (ECR) ITT Population EMA Primary Endpoint: Investigator Assessment of Clinical Response (IACR) at Test of Cure (mITT and CE-TOC Population) FDA and EMA Primary Endpoints 72-120 hours after first dose of study drug Improveme

  7. Slide 7: CABP Symptom Assessment for ECR

    LEAP 2 Phase 3 Trial Design CABP Symptom Assessment for ECR Symptom Absent (0) Mild (1) Moderate (2) Severe (3) Dyspnea Resolution (to pre-CABP baseline) or absence of dyspnea Dyspnea on exertion (e.g., climbing stairs) Dyspnea with normal/routine activities (e.g., walking) Dyspnea at rest or requir

  8. Slide 8: Trial Populations and Disposition

    LEAP 2 Phase 3 Trial Populations and Disposition High Patient Completion and Microbiological Isolate Recovery Rates 9 Category Lefamulin n (%) Moxifloxacin n (%) TOTAL n (%) All Randomized (ITT) 370 368 738 Modified ITT (mITT) 368 (99.5%) 368 (100%) 736 (99.7%) Clinically Evaluable-Test of Cure (CE-

  9. Slide 9: ITT Population Baseline Characteristics

    LEAP 2 Phase 3 Trial ITT Population Balanced Baseline Characteristics Between Treatment Groups 10 Category Lefamulin n (%) Moxifloxacin n (%) TOTAL n (%) Age <65 years 234 (63.2%) 227 (61.7%) 461 (62.5%) 65-74 78 (21.1%) 79 (21.5%) 157 (21.3%) >75 58 (15.7%) 62 (16.8%) 120 (16.3%) Demographics Male

  10. Slide 10: PORT Risk Classification: ITT Population

    LEAP 2 Phase 3 Trial PORT Risk Classification: ITT Population 11 PORT Class Lefamulin n (%) Moxifloxacin n (%) TOTAL n (%) I 1 (0.3%) 2 (0.5%) 3 (0.4%) II 183 (49.5%) 189 (51.4%) 372 (50.4%) III 145 (39.2%) 133 (36.1%) 278 (37.7%) IV 40 (10.8%) 42 (11.4%) 82 (11.1%) V 1 (0.3%) 2 (0.5%) 3 (0.4%)

  11. Slide 11: Trial Efficacy Results

    LEAP 2 TRIAL EFFICACY RESULTS

  12. Slide 12: Lefamulin Met FDA Primary Endpoint

    LEAP 2 Trial Efficacy Results 13 Lefamulin Met FDA Primary Endpoint 336 / 370 334 / 368 High Response Rates on Both Arms Delta (95% CI) 0.1 (-4.4, 4.5) 336 / 370 334 / 368

  13. Slide 13: Lefamulin Met EMA Co-Primary Endpoints

    LEAP 2 Trial Efficacy Results Lefamulin Met EMA Co-Primary Endpoints 14 Delta (95% CI) -3.9 (-8.2, 0.5) Delta (95% CI) -1.6 (-6.3, 3.1) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% IACR mITT IACR CE - TOC 87.5% 89.7% 89.1% 93.6% Percent Responders EMA Primary Endpoints: IACR in mITT and CE at TOC Lef

  14. Slide 14: ECR by PORT Risk Classification: ITT Population

    ECR by PORT Risk Classification: ITT Population Lefamulin Demonstrated High Response Rates Across All Severities of CABP 15 PORT Class Lefamulin Moxifloxacin Treatment Difference (95% CI) I 1/1 (100%) 2/2 (100%) - II 168/183 (91.8%) 176/189 (93.1%) -1.3 (-7.2, 4.6) III 132/145 (91.0%) 120/133 (90.2%

  15. Slide 15: High Response Rate Against Most Common Causes of CABP

    Lefamulin Demonstrated High Response Rate Against All of the Most Common Causes of CABP 16 Lefamulin Moxifloxacin Microbiological ITT (microITT) N = 205 N = 186 Baseline Pathogen ECR (%) ECR (%) Gram Positive S. pneumoniae 110/123 89.4% 115/126 91.3% Penicillin Susceptible 19/25 76.0% 36/38 94.7% Pe

  16. Slide 16: High Response Rate Against Most Common Causes of CABP (continued)

    Lefamulin Demonstrated High Response Rate Against All of the Most Common Causes of CABP 17 ECR by Baseline Pathogen – Typical Pathogens [micro ITT] continued Lefamulin Moxifloxacin Baseline Pathogen ECR (%) ECR (%) Gram Negative H. influenzae 50/56 89.3% 44/48 91.7% M. catarrhalis 18/21 85.7% 11/11

  17. Slide 17: Trial Safety and Tolerability Data

    LEAP 2 TRIAL SAFETY and TOLERABILITY DATA

  18. Slide 18: Overview of Adverse Events (mITT)

    Overview of Adverse Events (mITT) Low Rates of Discontinuation Observed 19 Patients with at Least One Lefamulin (n=368) Moxifloxacin (n=368) Treatment Emergent AE (TEAE) 120 (32.6%) 92 (25.0%) AE Leading to Discontinuation of Study Drug 11 (3.0%) 8 (2.2%) AE Leading to Withdrawal from Study 5 (1.4%)

  19. Slide 19: TEAEs > 1% in Either Arm: Safety Population

    20 TEAE Lefamulin (n=368) Moxifloxacin (n=368) Diarrhea/ Loose Stools 45 (12.2%) 4 (1.1%) Nausea 19 (5.2%) 7 (1.9%) Vomiting 12 (3.3%) 3 (0.8%) Hypertension 5 (1.4%) 5 (1.4%) Respiratory Tract Infection Viral 5 (1.4%) 1 (0.3%) Gastritis 4 (1.1%) 2 (0.5%) Pneumonia 4 (1.1%) 1 (0.3%) Chronic Obstructi

  20. Slide 20: Treatment Emergent Adverse Events of Interest

    Treatment Emergent Adverse Events of Interest 21 TEAEs in 17.9% and 7.6% of patients receiving lefamulin and moxifloxacin, respectively Diarrhea/ Loose Stools was observed in 12.2% and 1.1% of patients receiving lefamulin and moxifloxacin, respectively 1 case of C. difficile infection was reported i

  21. Slide 21: Gastrointestinal System Organ Class Adverse Events

    Gastrointestinal System Organ Class Adverse Events 22 Diarrhea/Loose Stools Diarrhea/loose stools were generally of short duration (approximately 2 days) and none led to discontinuation of lefamulin. Nausea Vomiting Nausea/vomiting generally mild and of limited duration. No patients discontinued due

  22. Slide 22: Treatment Emergent Adverse Events of Interest

    Treatment Emergent Adverse Events of Interest 23 TEAEs in 17.9% and 7.6% of patients receiving lefamulin and moxifloxacin, respectively Diarrhea/ Loose Stools was observed in 12.2% and 1.1% of patients receiving lefamulin and moxifloxacin, respectively 1 case of C. difficile infection was reported i

  23. Slide 23: Maximum Post Baseline Liver Enzymes: Safety Population

    Maximum Post Baseline Liver Enzymes: Safety Population Low Incidence of Hepatic Enzyme Elevations 24 Lab Parameter Lefamulin Moxifloxacin Any Post Baseline ALT >3xULN 15/355 (4.2%) 17/361 (4.7%) >5xULN 7/355 (2.0%) 3/361 (0.8%) >10xULN 1/355 (0.3%) 0/361 Any Post Baseline AST >3xULN 12/355 (3.4%) 8/

  24. Slide 24: Treatment Emergent Adverse Events of Interest

    Treatment Emergent Adverse Events of Interest 25 TEAEs in 17.9% and 7.6% of patients receiving lefamulin and moxifloxacin, respectively Diarrhea/ Loose Stools was observed in 12.2% and 1.1% of patients receiving lefamulin and moxifloxacin, respectively 1 case of C. difficile infection was reported i

  25. Slide 25: Maximum Post Dose QTcF Changes from Baseline

    Maximum Post Dose QTcF Changes from Baseline (mITT) 26 Parameter Lefamulin (n=368) Moxifloxacin (n=368) Any Post Baseline Increase >30 msec 56 (15.4%) 68 (18.5%) Any Post Baseline Increase > 60 msec 4 (1.1%) 7 (1.9%) Any Post Baseline Value > 500 msec 1 (0.3%) 2 (0.5%) Any Post Baseline Increase > 6

  26. Slide 26: Phase 3 Clinical Trials Achieved All Primary Endpoints

    LEAP Phase 3 Clinical Trials Achieved All Primary Endpoints

  27. Slide 27: Phase 3 Trials Achieved All Primary Endpoints: FDA Endpoint

    LEAP Phase 3 Clinical Trials Achieved All Primary Endpoints 28 For both the IV-to-Oral and Oral Trials of Lefamulin Compared to Moxifloxacin for CABP FDA Primary Endpoint: ECR LEAP 1 LEAP 2 Delta (95% CI) 0.1 (-4.4, 4.5) Delta (95% CI) -2.9 (-8.5, 2.8)

  28. Slide 28: Phase 3 Trials Achieved All Primary Endpoints: EMA Endpoints

    LEAP Phase 3 Clinical Trials Achieved All Primary Endpoints 29 For both the IV-to-Oral and Oral Trials of Lefamulin Compared to Moxifloxacin for CABP EMA Primary Endpoints: IACR in mITT and CE at TOC LEAP 1 LEAP 2 Delta (95% CI) -3.9 (-8.2, 0.5) Delta (95% CI) -2.6 (-8.9, 3.9) Delta (95% CI) --1.6 (

  29. Slide 29: Percent of Patients Discontinuing Study Drug

    30 % of Patients Discontinuing Study Drug Low Rate of Premature Discontinuations of Study Drug Across Phase 3 Program LEAP 1 IV to Oral LEAP 2 Oral Only

  30. Slide 30: Lefamulin: A Promising Potential Treatment Option for CABP

    Lefamulin: A Promising Potential Treatment Option for CABP Lefamulin met all primary FDA and EMA endpoints in both LEAP 1 and LEAP 2 trials 31 Complete Spectrum of Coverage of Main CABP Pathogens Monotherapy shown to provide the appropriate coverage with a low risk of C. difficile infection Generall

  31. Slide 31: Acknowledgments

    Acknowledgments 32 We are grateful for the participation and contributions of the following in the LEAP Program: Anita Das, Ph. D. Gary Moore, M.Sc. The Nabriva Therapeutics team Patients and families Clinical investigators and their staff Collaborating research organizations

  32. Slide 32: Recent and Anticipated Lefamulin Milestones

    May 2018 Topline data from LEAP 2 Phase 3 trial for CABP Recent and Anticipated Lefamulin Milestones 33 Sept 2017 Topline data from LEAP 1 Phase 3 trial for CABP Mid 2018 Pediatric Study Initiation Q4 2018 Regulatory filing in US (priority review request to FDA) for CABP

  33. Slide 33: CABP: Underserved by Anti-Infective Portfolios of Other Companies

    34 Gram Negative or MRSA Products Broad Spectrum Products CABP Focus with MRSA Coverage 34 CABP: Underserved by Anti-Infective Portfolios of Other Companies A Potentially Significant Opportunity for Lefamulin

  34. Slide 34: Nabriva: Addressing the Demand for New Antibiotics

    Nabriva: Addressing the Demand for New Antibiotics Lefamulin, the lead molecule of a new class of antibiotics in clinical development for CABP, demonstrated positive topline results in both the LEAP 1 and LEAP 2 Phase 3 trials, with an NDA filing expected in the fourth quarter of 2018 Pre-commercial

  35. Slide 35: Nabriva: Addressing the Demand for New Antibiotics

    Nabriva: Addressing the Demand for New Antibiotics Lefamulin, the lead molecule of a new class of antibiotics in e clinical development for CABP, demonstrated positive topline results in both the LEAP 1 and LEAP 2 Phase 3 trials, with an NDA filing expected in the fourth quarter of 2018 e Pre-commer

  36. Slide 36: Questions?

    Questions?

Nabriva Therapeutics — Technical Presentation (May 2018) on 6ix